AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $63.83
- 52-wk high
- $70.98
- High
- $65.33
- 52-wk low
- $49.26
- Low
- $63.64
- Prev close
- $64.63
- Mkt cap
- $12.51B
- P/E
- 174.7x
- Volume
- 1.95M
- Fwd P/E
- 10.1x
- Beta
- 0.24
- P/S
- 3.7x
- P/B
- 2.0x
- Profit margin
- +2.1%
- Op margin
- +21.2%
- ROE
- +1.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 13.9% above what analysts expected.
Earnings per share
$0.79 expected
Reports Oct 26, 2026, in 46 days
EPS expected
$1.22 to $1.51
Revenue expected
20 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $776.1M | $874.6M | $766.2M | $989.7M |
| Cost of what it sold | $140.1M | $295.1M | $195.0M | $202.8M |
| Gross profit | $636.0M | $579.5M | $571.2M | $786.9M |
| What it spent | ||||
| Research and development | $409.5M | $192.4M | $178.8M | $207.0M |
| Sales and admin | $137.1M | $802.1M | $133.4M | $253.3M |
| Other operating costs | $136.1M | -$494.4M | $129.4M | $215.7M |
| Total operating expenses | $682.7M | $500.1M | $441.6M | $676.0M |
| What was left | ||||
| Operating profit | -$46.7M | $79.4M | $129.6M | $110.9M |
| Interest on debt | $2.6M | $2.8M | $15.0M | $63.3M |
| Profit before tax | -$26.3M | -$27.2M | $141.2M | $61.4M |
| Tax | $4.4M | $19.4M | $35.7M | $16.6M |
| Net profit | -$30.7M | -$46.6M | $105.5M | $44.8M |
| EBITDA | -$5.3M | -$3.9M | $172.6M | $222.3M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
(BMRN) Movement Within Algorithmic Entry Frameworks
Leans bearishSep 9BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence
BullishSep 9EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock
Leans bearishSep 4How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
Leans bullishSep 3How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
Leans bullishSep 3BioMarin Announces Close of the Alesta Therapeutics Acquisition
BullishSep 1BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BullishAug 31Raymond James raises BioMarin stock price target on patent settlement
BullishAug 31